scholarly journals Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Daniel A. Hescheler ◽  
Burkhard Riemann ◽  
Milan J. M. Hartmann ◽  
Maximilian Michel ◽  
Michael Faust ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Targeted Therapy ◽  
Drug Sensitivity ◽  
Genetic Alterations ◽  
Papillary Thyroid ◽  
Tall Cell Variant ◽  
Tall Cell ◽  
Cell Variant ◽  
Approved Drugs ◽  
Fda Approved Drugs

BackgroundA limited number of targeted therapy options exist for papillary thyroid cancer (PTC) to date. Based on genetic alterations reported by the “The Cancer Genome Atlas (TCGA)”, we explored whether PTC shows alterations that may be targetable by drugs approved by the FDA for other solid cancers.MethodsDatabases of the National Cancer Institute and MyCancerGenome were screened to identify FDA-approved drugs for targeted therapy. Target genes were identified using Drugbank. Genetic alterations were classified into conferring drug sensitivity or resistance using MyCancerGenome, CiViC, TARGET, and OncoKB. Genomic data for PTC were extracted from TCGA and mined for alterations predicting drug response.ResultsA total of 129 FDA-approved drugs with 128 targetable genes were identified. One hundred ninety-six (70%) of 282 classic, 21 (25%) of 84 follicular, and all 30 tall-cell variant PTCs harbored druggable alterations: 259 occurred in 29, 39 in 19, and 31 in 2 targetable genes, respectively. The BRAF V600 mutation was seen in 68% of classic, 16% of follicular variant, and 93% of tall-cell variant PTCs. The RET gene fusion was seen in 8% of classic PTCs, NTRK1 and 3 gene fusions in 3%, and other alterations in <2% of classic variant PTCs. Ninety-nine of 128 (77%) FDA-approved targetable genes did not show any genetic alteration in PTC. Beside selective and non-selective BRAF-inhibitors, no other FDA-approved drug showed any frequent predicted drug sensitivity (<10%).ConclusionTreatment strategies need to focus on resistance mechanisms to BRAF inhibition and on genetic alteration–independent alternatives rather than on current targeted drugs.

scholarly journals Central Neck Compartment Metastases in Tall-Cell Variant of Papillary Thyroid Cancer

2011 ◽  
Vol 145 (2_suppl) ◽  
pp. P162-P162
Author(s):  
Benjamin R. Roman ◽  
Elana Opher ◽  
Gady Har-El ◽  
John Carew
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Central Neck ◽  
Papillary Thyroid ◽  
Tall Cell Variant ◽  
Tall Cell ◽  
Cell Variant

Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus?

Thyroid ◽  
2017 ◽  
Vol 27 (12) ◽  
pp. 1498-1504 ◽  
Author(s):  
Juan C. Hernandez-Prera ◽  
Rosalie A. Machado ◽  
Sylvia L. Asa ◽  
Zubair Baloch ◽  
William C. Faquin ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Tall Cell Variant ◽  
Tall Cell ◽  
Cell Variant

Tall-Cell Variant of Papillary Thyroid Cancer: Disregarded Entity?

1997 ◽  
Vol 21 (1) ◽  
pp. 15-21 ◽  
Author(s):  
A. Rüter ◽  
R. Nishiyama ◽  
S. Lennquist
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Tall Cell Variant ◽  
Tall Cell ◽  
Cell Variant

scholarly journals MON-442 Tall Cell Variant of Papillary Thyroid Carcinoma Presenting Acutely as a Right Thyroid Mass and Thyroiditis - an Unusual Presentation

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Itivrita Goyal ◽  
Salman Zahoor Bhat ◽  
Manav Batra ◽  
Abhijana Karunakaran
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Thyroid Lobe ◽  
Suppurative Thyroiditis ◽  
Early Course ◽  
Tall Cell Variant ◽  
Tall Cell ◽  
Cell Variant

Abstract INTRODUCTION Aggressive malignant thyroid tumors (AMTT) can rarely present with signs and symptoms mimicking that of acute suppurative thyroiditis (AST). In its early course, correct diagnosis may be difficult but a prompt recognition is crucial. We report an interesting case of an aggressive papillary thyroid cancer with presenting acute symptoms masquerading as AST. CLINICAL CASE A 50-year-old Caucasian male was admitted for 2 day history of sore throat, odynophagia, low grade fever with a tender and enlarging right neck swelling, not improving with oral antibiotics. CT neck showed a 5.8 x 4.5cm mass in right thyroid lobe with shallow retropharyngeal effusion. Labs showed elevated WBC 10.7 x 109/L (4–10.5), ESR 20 mm/hr (0–12), CRP 92.93 mg/L (0.2–10), with negative rapid strep and IgM for viruses EBV and CMV. Thyroid function tests were normal. Ultrasound neck showed an ill-defined 6.5 cm hypoechoic mass with cystic component and increased vascularity and calcification, replacing the right thyroid lobe. Due to concern for thyroid abscess he underwent urgent aspiration. Fluid analysis and cultures were negative for bacterial source. FNA (fine needle aspiration) of one specimen was suspicious for follicular neoplasm with predominant hurtle cells and suspicious for thyroid neoplasm with papillary architecture in the other. Core biopsy was suspicious for papillary carcinoma but limited due to scant amount of tissue. Affirma unavailable due to insufficient RNA yield. Flow cytometry was negative for abnormal lymphocyte population. Repeat CT neck 3 weeks later was concerning for metastatic lymphadenopathy. He underwent total thyroidectomy with lymph node (LN) dissection and pathology showed papillary thyroid cancer, tall cell variant, tumor size 6 cm, predominantly hemorrhagic, extending to perithyroidal strap muscles and involving 5/6 LN in right trachea-esophageal groove. It was a stage I, pT3bN1aMx cancer. Subsequently, he underwent thyrogen stimulated I-131 ablation of residual thyroid carcinoma with pretherapy scan showing increased uptake in thyroid bed and a satellite lesion suspicious for LN metastasis. Post-ablative scan showed no other new lesions. He is now on levothyroxine suppressive therapy. CONCLUSION Early course of AMTT can rarely present as AST, both being progressive and fatal diseases. Our case had a typical presentation of AST, causing delay in diagnosis of his very aggressive form of thyroid cancer. Gross pathology showed predominantly hemorrhagic areas in the tumor with central necrosis, which was likely the cause of acute mass with systemic signs suspicious for infection. One should consider an alternative diagnosis in suspected cases of AST in the absence of positive cultures or lack of improvement with parenteral antibiotics. It is imperative to make a diagnosis without any delay as prognosis for either condition depends on prompt recognition and treatment.

scholarly journals Prognostic Outcomes of Tall Cell Variant Papillary Thyroid Cancer: A Meta-Analysis

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Scharukh Jalisi ◽  
Tiffiny Ainsworth ◽  
Michael LaValley
Keyword(s):  
Thyroid Cancer ◽  
Confidence Interval ◽  
Papillary Thyroid Cancer ◽  
Odds Ratio ◽  
Meta Analysis ◽  
Papillary Thyroid ◽  
Tall Cell Variant ◽  
Tall Cell ◽  
Cell Variant ◽  
Related Mortality

Objective. To evaluate the prognosis of tall cell variant (TCV) compared to usual variant (UV) papillary thyroid cancer by comparing disease-related mortality and recurrence data from published studies.Methods. Ovid MEDLINE keyword search using “tall cell variant papillary thyroid cancer” was used to identify studies published in English that calculated disease-related mortality and recurrence rates for both TCV and UV.Results. A total of 131 cases of tall cell variant papillary thyroid cancer were reviewed. The combined odds ratio of recurrence for TCV compared to UV is 4.50 with a 95% confidence interval from 2.90 to 6.99. For disease-related mortality, the combined odds ratio for TCV was compared to UV of 14.28 with a 95% confidence interval from 8.01 to 25.46.Conclusion. Currently published data suggests that TCV is a negative prognostic indicator in papillary thyroid cancer and requires aggressive therapy. This meta-analysis provides the largest prognostic data series on TCV in the literature and clearly identifies the need for accurate pathological identification of TCV and its further study as an independent prognostic factor.

BRAF-positive paucicellular variant of anaplastic carcinoma in the presence of tall cell variant papillary thyroid cancer

2017 ◽  
Vol 79 (3) ◽  
pp. 27
Author(s):  
O. V. Dolzhansky ◽  
E. M. Paltseva ◽  
D. N. Khmelkova ◽  
F. A. Konovalov ◽  
I. V. Kanivets ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Anaplastic Carcinoma ◽  
Papillary Thyroid ◽  
Tall Cell Variant ◽  
Tall Cell ◽  
Cell Variant
Sign in / Sign up

Export Citation Format

Share Document